Experiences with

Lopinavir / Ritonavir

As an update to several earlier posts about the use of Pemivibart for COVID. It seems the FDA is about to limit its use to only as a pre-exposure prophylaxis agent for COVID-19 in immunocompromised patients. Here is the MedPage article dated August 27, 2024 in full: * * * [i]MedPage Today - Infectious

...but is it ineffective in younger age groups? The issue is, the study in question https://www.nejm.org/doi/full/10.1056/NEJMoa2204919?query=TOC&cid=NEJM%20eToc,%20August%2025,%202022%20DM1379474_NEJM_Non_Subscriber&bid=1131122421 looked at "Nirmatrelvir Use and Severe Covid-19 Outcomes during the

Dear All, After six emails I got a response from my MP ... nothing spectacular but nonetheless helpful. However, the apparent preference to depend on treatment rather than prevention is worrying. "Thank you for your correspondence of 25 April on behalf of your constituent, about COVID-19 treatments.

Hi . I have GPA and I am identified as being clinically extremely vulnerable due to the fact that I take immune suppressants (Azathioprine and Prednisolone). I recently became infected with Covid 19 and became very ill. Because I became ill on the weekend I so had to book a courier to pick up my PCR

Hi everyone, I have updated our website article about the COVID-19 treatments for those who are at higher risk for severe illness from COVID-19 infection. https://www.lupusuk.org.uk/covid-19-treatments/ There have been a couple of important changes: 1.Lateral flow tests are now accepted as confirmation

This post, prepared in collaboration with        AussieNeil , draws together some earlier posts relating to SARS-CoV-2 infection and CLL. COVID-19 RISK FOR CLL PATIENTS Due to their impaired humoral and cellular immune function, CLL patients are at particular risk for infection, including

This is from the FDA fact sheet- PAXLOVID is contraindicated with drugs that are potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. PAXLOVID cannot be started immediately

On 22 December the U.S. Food and Drug Administration issued an emergency use authorisation (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults. Pfizer has also announced an agreement

Thousands of vulnerable patients could be taking ground-breaking COVID-19 antivirals this winter after the government announced deals to secure 2 new treatments. These treatments should speed up recovery time for COVID-19 patients and the most vulnerable will be eligible first, including the elderly

ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC, Convenient Approach Amid COVID-19 Pandemic February 8, 2021 Dr. Ulka N. Vaishampayan ModraDoc006, a novel oral docetaxel formulation, has advantages as a convenient, oral, and better-tolerated potential therapeutic option for patients

A triple-antiviral therapy regimen of interferon-beta1, lopinavir/ritonavir, and ribavirin shortened median time to COVID-19 viral negativity (mild to moderate cohorts) in a small, randomized trial (n=84) done by the University of Hong Kong (China).

They include: Lopinavir-Ritonavir, commonly used to treat HIV Dexamethasone, a type of steroid use in a range of conditions to reduce inflammation Hydroxychloroquine, a treatment for malaria The trial is being conducted in over 130 NHS hospitals across the UK.

SOLIDARITY is examining four promising drug regimens: 1) Remdesivir—an experimental antiviral medication; 2) Chloroquine and hydroxychloroquine—malaria medications; 3) Lopinavir and ritonavir—two HIV drugs that may be useful in combination; and 4) Lopinavir, ritonavir plus interferon-beta, a medication

The four treatments to be studied are remdesivir, lopinavir and ritonavir in combination, the latter being administered with or without interferon beta and hydroxychloroquine, French public health research body Inserm said in a statement on Sunday.

The Chinese admit per the NEJM article that the HIV anti-viral medicine Lopinavir–Ritonavir was a failure in their clinical trial (n=199) of this drug on "severe" cases. #1 “it has no observable effect in stopping the virus”. #2 adverse events were common and severe.

It talks specifically about Remdesivir, Hydroxychloroquine, Umifenovir, Baloxavir, Favipiravir, Lopinavir and Ritonavir. (Click on the link above to read specifics on each of these medications).

Kaletra This combination of two antiviral drugs, lopinavir and ritonavir, is used to combat HIV. It's widely available, and several clinical trials around the world are underway. The two drugs, both protease inhibitors, have different but complementary roles when used in combination.

Hi, this post is about my father, he is 62 years. He was diagnosed with hepatitis and ultrasound confirmed nodules, cirrhosis and ascites. He never took alcohol all his life. When he was admitted in hospital, he was given human albumin (via IV), diuretics and Ritonavir (antiretroviral I guess). Recent

Antiviral medications are developed by Gilead Sciences, Inc, USA. Ledipasvir/sofosbuvir, sold under the trade name Harvoni among others, is a medication used to treat hepatitis C. It is a combination of ledipasvir and sofosbuvir. Cure rates are 94% to 99% in people infected with hepatitis C virus (HCV

Clarithromycin, darunavir, grapefruit juice, itraconazole, ketoconazole, lopinavir, mifepristone, nefazodone, nelfinavir, ombitasvir, paritaprevir, ritonavir, posaconazole, saquinavir, telaprevir, telithromycin, verapamil, voriconazole.